Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Lancet (London, England)
|
April 16, 2011
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial
Taraz Samandari, Tefera B Agizew, Samba Nyirenda, et al.
MMWR. Morbidity and Mortality Weekly Report
|
February 2, 2023
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023
Ruth Link-Gelles, Allison Avrich Ciesla, Lauren E Roper, et al.
The New England Journal of Medicine
|
December 14, 2011
Three months of rifapentine and isoniazid for latent tuberculosis infection
Timothy R Sterling, M Elsa Villarino, Andrey S Borisov, et al.
MMWR. Morbidity and Mortality Weekly Report
|
May 5, 2022
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022
Namrata Prasad, Gordana Derado, Srinivas Acharya Nanduri, et al.
MMWR. Morbidity and Mortality Weekly Report
|
March 18, 2021
Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021
Amadea Britton, Kara M Jacobs Slifka, Chris Edens, et al.
MMWR. Morbidity and Mortality Weekly Report
|
August 26, 2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021
Srinivas Nanduri, Tamara Pilishvili, Gordana Derado, et al.
SSM - Population Health
|
September 27, 2016
Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study
Ruth Link-Gelles, Daniel Westreich, Allison E Aiello, et al.
BMJ Open
|
August 31, 2017
Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA
Ruth Link-Gelles, Daniel Westreich, Allison E Aiello, et al.
Plos One
|
October 19, 2020
The epidemiology and estimated etiology of pathogens detected from the upper respiratory tract of adults with severe acute respiratory infections in multiple countries, 2014-2015
Jennifer Milucky, Tracy Pondo, Christopher J Gregory, et al.
The Lancet. Global Health
|
August 12, 2022
Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study
Melissa L Arvay, Nong Shang, Shamim A Qazi, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Lancet (London, England)
|
April 16, 2011
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial
Taraz Samandari, Tefera B Agizew, Samba Nyirenda, et al.
MMWR. Morbidity and Mortality Weekly Report
|
February 2, 2023
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023
Ruth Link-Gelles, Allison Avrich Ciesla, Lauren E Roper, et al.
The New England Journal of Medicine
|
December 14, 2011
Three months of rifapentine and isoniazid for latent tuberculosis infection
Timothy R Sterling, M Elsa Villarino, Andrey S Borisov, et al.
MMWR. Morbidity and Mortality Weekly Report
|
May 5, 2022
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022
Namrata Prasad, Gordana Derado, Srinivas Acharya Nanduri, et al.
MMWR. Morbidity and Mortality Weekly Report
|
March 18, 2021
Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021
Amadea Britton, Kara M Jacobs Slifka, Chris Edens, et al.
MMWR. Morbidity and Mortality Weekly Report
|
August 26, 2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021
Srinivas Nanduri, Tamara Pilishvili, Gordana Derado, et al.
SSM - Population Health
|
September 27, 2016
Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study
Ruth Link-Gelles, Daniel Westreich, Allison E Aiello, et al.
BMJ Open
|
August 31, 2017
Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA
Ruth Link-Gelles, Daniel Westreich, Allison E Aiello, et al.
Plos One
|
October 19, 2020
The epidemiology and estimated etiology of pathogens detected from the upper respiratory tract of adults with severe acute respiratory infections in multiple countries, 2014-2015
Jennifer Milucky, Tracy Pondo, Christopher J Gregory, et al.
The Lancet. Global Health
|
August 12, 2022
Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study
Melissa L Arvay, Nong Shang, Shamim A Qazi, et al.
Page
of 5